Latest / CME Outfitters Medical Education / Global Guidelines and Strategies for HIV Screening and Diagnosis
Transcript
- 0:01SPEAKER_04: Hello and welcome.
- 0:03SPEAKER_04: On behalf of CME Outfitters, I'd like to welcome you and thank you for joining us.
- 0:08SPEAKER_04: This activity is titled Global Guidelines and Strategies for HIV Screening and Diagnosis.
- 0:15SPEAKER_04: This program has been supported by an independent educational grant from Gilead Sciences.
- 0:22SPEAKER_04: Today's activity may include discussion of products or uses that are not approved by the FDA or relevant regulatory authorities.
- 0:31SPEAKER_04: Faculty will identify investigational or off-label uses when discussed.
- 0:37SPEAKER_04: Reimbursement, public funding, and access pathways vary by country and change frequently.
- 0:42SPEAKER_04: Please consult current local or national guidance.
- 0:47SPEAKER_04: So, hi everyone, I'm Dr.
- 0:48SPEAKER_04: Oni Blackstock.
- 0:49SPEAKER_04: I'm a primary care and HIV physician based out of New York City.
- 0:53SPEAKER_04: I am founder and executive director of health justice, a consulting and research organization.
- 0:59SPEAKER_04: And I previously served as assistant commissioner for the New York City Health Department's Bureau of HIV, where I led the city's response to the HIV epidemic.
- 1:10SPEAKER_04: And I'm delighted to be joined by colleagues whose collective work in HIV spans several continents.
- 1:17SPEAKER_04: Doctors Orkin, Solomon, and Tatanji.
- 1:20SPEAKER_04: Would you please introduce yourselves and provide a little about your background in HIV, starting with Dr.
- 1:27SPEAKER_04: Orkin?
- 1:28SPEAKER_04: And after our formal introductions, we'll switch to first names throughout the presentation.
- 1:32SPEAKER_04: So Dr.
- 1:33SPEAKER_04: Orkin.
- 1:34SPEAKER_00: Wonderful.
- 1:35SPEAKER_00: Thank you so much, Dr.
- 1:36SPEAKER_00: Blackstock.
- 1:37SPEAKER_00: So uh I am Chloe Orkin and uh I'm a clinician in London, in a pool part of London, and I'm a professor of infection and inequities at Queen Mary University of London.
- 1:49SPEAKER_00: And I've spent quite a bit of time in my life working on introduction of routine bloodborne virus testing within the UK emergency department context.
- 2:03SPEAKER_01: Hi everyone, I'm Dr.
- 2:04SPEAKER_01: Sunil Sua Solomon.
- 2:05SPEAKER_01: I'm a professor of medicine and epidemiology from the Johns Hopkins University.
- 2:10SPEAKER_01: Most of my work has been around access to HIV testing and HIV treatment globally, primarily outside of the US settings, mostly in India, but it's also with a special emphasis on key populations such as people who inject drugs, men who have sex with men, and trans people.
- 2:27SPEAKER_03: Hi everyone.
- 2:29SPEAKER_03: My name is Bahuma Titanji.
- 2:31SPEAKER_03: I am an infectious diseases physician and HIV clinician based out of Atlanta, Georgia.
- 2:38SPEAKER_03: I'm an assistant professor of medicine at Emory University.
- 2:41SPEAKER_03: My work in HIV has spanned probably now 10 years, both working in the African context, particularly in Cameroon, and now also in the US within the epicenter of the HIV epidemic here, which is the Southeast United States.
- 3:00SPEAKER_03: My research has focused primarily on HIV drug resistance and more recently also chronic comorbidities in people with HIV and long-acting injectable antiviral drugs.
- 3:12SPEAKER_04: Wonderful, thank you.
- 3:14SPEAKER_04: So to frame today's discussion, let's review our primary learning objective, and that is to integrate guideline recommendations for HIV testing into routine practice.
- 3:28SPEAKER_04: So we'll begin with an audience response question.
- 3:31SPEAKER_04: And the question is when do you offer an HIV test to a new patient entering your care?
- 3:57SPEAKER_04: Okay, now let's dive right in and frame why routine HIV testing is so important.
- 4:04SPEAKER_04: So globally, um, you may know that more than 40 million people are living with HIV, yet significant gaps remain across diagnosis, linkage, treatment, and viral suppression.
- 4:18SPEAKER_04: We know that earlier diagnosis creates an opportunity for timely linkage and differentiated service delivery.
- 4:25SPEAKER_04: Sunil, could you put current progress toward the UNAIDS 95, 95, 95 targets into context for us?
- 4:35SPEAKER_01: Sure.
- 4:35SPEAKER_01: I think like you mentioned, diagnosis is the first step to either the prevention cascade or the treatment cascade.
- 4:41SPEAKER_01: We have great treatment and prevention options, but unless you screen someone, they're not eligible for each of these pathways.
- 4:48SPEAKER_01: So the UNAID set up these ambitious targets, the 95-95-95 targets, wherein they hope that 95% of people living with HIV are aware of their status, and 95% of those who are aware are receiving antiretroviral therapy, and 95% of those on antiretroviral therapy are virologically suppressed.
- 5:08SPEAKER_01: Unfortunately, globally, that number stands at 87, 77, and 73 right now.
- 5:14SPEAKER_01: We have a long way to go, but two things I want to point out is there is a lot of heterogeneity in just even those numbers: 87, 77, 73.
- 5:24SPEAKER_01: For example, some countries in sub-Saharan Africa have actually hit those targets.
- 5:28SPEAKER_01: And then you have some countries like in Central Asia that are very far from those targets.
- 5:33SPEAKER_01: And sometimes when you go even into one country, for example, if you go into India, the 95, 95, 95 targets among the general population is extremely different from what it is among people who inject drugs, where we are struggling to get it like 40 or 50% for that first 95%.
- 5:51SPEAKER_01: So those are the targets, but there is a lot of heterogeneity across countries and across populations.
- 5:58SPEAKER_04: So that's a really important point that the global numbers that we're seeing can mass what's actually happening in specific communities and regions.
- 6:06SPEAKER_04: And I think another important point to highlight is that many new HIV transmissions occur among people who are not aware of their status and therefore are not in care or receiving treatment.
- 6:18SPEAKER_04: And so HIV testing is so critically important because of that.
- 6:23SPEAKER_04: So before we move into the guidelines, um, just wanting to clarify what a status neutral approach means.
- 6:31SPEAKER_04: Some of our audience may be familiar with this term.
- 6:34SPEAKER_04: So it means that every HIV test should lead to an appropriate next step.
- 6:39SPEAKER_04: So people who test HIV negative should be offered appropriate prevention services.
- 6:44SPEAKER_04: Those include PrEP, PEP, post-exposure prophylaxis, condoms, harm reduction services, and other ongoing support.
- 6:53SPEAKER_04: A reactive test should lead to confirmatory testing that, if confirmed, then prompts linkage to HIV care and treatment.
- 7:03SPEAKER_04: And for people living with HIV, we know that effective treatment supports durable viral suppression and that undetectable equals untransmittable.
- 7:13SPEAKER_04: So that when someone is taking their medication as prescribed and they're undetectable, they have effectively no risk of passing HIV on to their sexual partners.
- 7:25SPEAKER_04: So in the US, um CDC recommends that everyone between the ages of 13 and 64 receive at least one HIV test during their lifetime.
- 7:37SPEAKER_04: The U.S.
- 7:38SPEAKER_04: Preventive Services Task Force currently recommends screening adolescents and adults ages 15 to 65.
- 7:46SPEAKER_04: And both of those recommendations also extend testing beyond those age ranges when relevant exposures exist or there are clinical characteristics that indicate that testing may be helpful.
- 8:00SPEAKER_04: For people with ongoing exposures, testing should occur at least annually and in some circumstances every three to six months.
- 8:10SPEAKER_04: Opt-out testing is also really important because, again, it normalizes screening as part of routine care and also reduces the stigma associated with selectively offering an HIV test.
- 8:21SPEAKER_04: And with opt-out testing, it means patients are notified that the test will be done and it proceeds automatically unless they explicitly decline the test.
- 8:35SPEAKER_04: So let's take a moment for another polling question.
- 8:39SPEAKER_04: So for the audience, how often do you recommend HIV testing for a patient with ongoing exposure?
- 9:05SPEAKER_04: So now, Sunil, let's place that recommendation within the broader WHO guidance.
- 9:11SPEAKER_04: Could you provide a brief overview of what the WHO recommends regarding HIV testing frequency?
- 9:20SPEAKER_01: Sure.
- 9:21SPEAKER_01: So the WHO recommendations vary depending on the population group.
- 9:25SPEAKER_01: And I want to say it up front, and I will probably say it again, that this is a minimum and not like an aspirational ceiling that we should be going towards.
- 9:33SPEAKER_01: So for populations like people who inject drugs in their partners, people engaged in transactional sex, people who have multiple partners or adolescents with known exposure factors, you want to try and screen them at least annually for HIV infection.
- 9:46SPEAKER_01: Similarly, for men who have sex with men, it should be at least annually, with if there is ongoing risk exposure every three to six months.
- 9:55SPEAKER_01: The other thing I think many of you will be familiar with is index testing or contact testing, which is partners and contacts of people living with HIV.
- 10:02SPEAKER_01: So that needs to be done at least once at baseline and then continually through the process.
- 10:06SPEAKER_01: And this is something that's standard in most PEPPAR programs globally.
- 10:11SPEAKER_01: For pregnant people at the first antenatal visit, and again repeat at third trimester for delivery, especially in high prevalence settings, because there are medications you could give to the mother to prevent transmission, even if diagnosed at a late point in time.
- 10:24SPEAKER_01: And during postpartum and breastfeeding, it's periodic retesting.
- 10:28SPEAKER_01: And again, like I said, these are a minimum.
- 10:32SPEAKER_01: Honestly, I believe like anyone who needs an HIV test should have access and should be able to get tested.
- 10:38SPEAKER_04: Definitely.
- 10:38SPEAKER_04: So thank you, Singil, for providing that foundation.
- 10:42SPEAKER_04: And so we know that across the CDC, the European AIDS Clinical Society, the World Health Organization, and other aligned national guidance, the common direction is around proactive HIV testing.
- 10:55SPEAKER_04: However, the emphasis and implementation of HIV testing differs across regions.
- 11:01SPEAKER_04: So I'd like to delve into that.
- 11:03SPEAKER_04: So, Chloe, let's begin with the UK and European perspective.
- 11:09SPEAKER_00: Sure.
- 11:09SPEAKER_00: So I think there are some differences here.
- 11:11SPEAKER_00: So the European AIDS Clinical Society supports proactive testing.
- 11:16SPEAKER_00: And this includes differentiated types of testing such as self-testing.
- 11:20SPEAKER_00: But I'm going to talk a little bit about the UK setting.
- 11:24SPEAKER_00: Because in the UK, HIV testing has been built into the government strategy as a national imperative.
- 11:32SPEAKER_00: And for a very long time in the UK, testing has been integrated into sexual health services.
- 11:39SPEAKER_00: And by doing that, we've reached a point where 95% of people living with HIV are diagnosed, 99% of those diagnosed are receiving anti-retroviral therapy, and 98% of those on treatment are virally suppressed.
- 11:53SPEAKER_00: However, we still have an issue with late diagnosis, and this is why sort of the next step of our political focus has emerged, because right now, 40% of adults newly diagnosed with HIV were diagnosed late.
- 12:07SPEAKER_00: This means with CD4 counts less than 350.
- 12:10SPEAKER_00: And we know that people who are diagnosed late are around 10 times more likely to die within a year.
- 12:16SPEAKER_00: And as has already been mentioned, sometimes the surveillance figures can hide the groups that are most affected.
- 12:22SPEAKER_00: So in gay, bisexual and other men who have sex with men, there are substantially lower rates of late diagnosis than other groups, whereas in heterosexual men, people of black African heritage and older adults, the rates are much higher.
- 12:37SPEAKER_00: So healthcare leaders and policymakers have acknowledged the necessity for a more effective HIV testing strategy to end the epidemic by 2030.
- 12:45SPEAKER_00: So when we do testing via a risk-based approach outside of sexual health services, this hasn't really worked for us.
- 12:53SPEAKER_00: So we've got to a point where we have a guideline recommended opt-out testing in high prevalence areas in all emergency departments with a prevalence of 0.5% or more.
- 13:04SPEAKER_00: And this has been going on since 2022.
- 13:07SPEAKER_00: And we've now tested, we've had done 10 million tests across 79 sites and made 10,000 diagnoses.
- 13:15SPEAKER_00: And most of the people diagnosed, more than 70%, have had no record of a previous bloodborne viral test.
- 13:21SPEAKER_00: So that's kind of where we have got to in terms of our work.
- 13:24SPEAKER_00: And when we do the testing, we take a bloodborne virus-based approach.
- 13:28SPEAKER_00: We don't just test for HIV to reduce stigma.
- 13:31SPEAKER_00: We also test for hepatitis B and hepatitis C.
- 13:34SPEAKER_00: So that's you know pretty much a summary of our approach.
- 13:37SPEAKER_04: Oh, that's great.
- 13:38SPEAKER_04: So it's like a systemic approach, um, focusing on areas of high prevalence, um, what you know, emergency departments where people maybe are coming in who may not have primary care.
- 13:47SPEAKER_04: So that's really um exciting to hear, Chloe.
- 13:51SPEAKER_04: But what do you see as the largest gaps um between the guideline recommendations and delivery and the areas of the world where you have experience?
- 14:00SPEAKER_03: Yeah, I think that the biggest issue that we're still facing is the heterogeneity in terms of who is actually able to access or be offered testing for HIV.
- 14:11SPEAKER_03: Thinking specifically about the Cameroonian context, which is a setting where same-sex relationships are still criminalized, we're not yet reaching men who have sex with men with regards to engaging them in HIV testing to a level that is recommended or indicated.
- 14:30SPEAKER_03: And if you don't reach specific groups that may have a higher risk of having HIV, then effectively you're not able to address all the touch points of the epidemic and ensure that people who need care are being linked to care.
- 14:46SPEAKER_03: Additionally, while testing of pregnant people is quite good because every pregnant person who shows up for a prenatal assessment will get offered a test at intake and will also get offered a test if they appear in the treatment center at delivery and in the maternity, they are able to get linked to care.
- 15:08SPEAKER_03: But in contrast, their male partners are not accessing testing to the same degree.
- 15:15SPEAKER_03: Now, on the flip side, in Atlanta, Georgia, which is quite a different context uh from uh Cameroon, where we have available testing and a lot of the local health systems have incorporated testing for HIV to be offered to anyone who comes in contact with an emergency uh department.
- 15:36SPEAKER_03: This has really enabled a lot of people uh to get tested, particularly if you don't have on record an HIV test within the past 12 months.
- 15:45SPEAKER_03: With that being said, there's still a lot of stigma about around uh testing for HIV and taking the test results to that next level of being really status neutral and offering resources, uh, whatever the outcome of the test is.
- 16:03SPEAKER_03: So very different settings, lots of heterogeneity around how well we're doing in terms of offering um uh testing to key groups and also in terms of linkage to care.
- 16:15SPEAKER_04: Okay, wonderful.
- 16:16SPEAKER_04: Thank you for sharing that with us and hearing some commonalities with, for instance, the emergency department um-based testing.
- 16:23SPEAKER_04: Umil, what regional nuances um can you share about um the context in which you're more familiar with in terms of HIV testing to practice?
- 16:32SPEAKER_01: So I think if you're looking at Asia, and if you just look at India and China, for example, that's one-third of the global population, right?
- 16:38SPEAKER_01: So the scale of people in these countries is much higher.
- 16:43SPEAKER_01: And so I think a lot like the WHO guidance just lays the foundation, but that needs to be adapted to the local epidemiology, the health system capacity, what resources are available in these different countries to really be efficient.
- 16:57SPEAKER_01: I think the one point that Chloe made, which I think is extremely relevant, is many of these countries in Asia have very siloed programs, so they have an HIV program and a hepatitis program.
- 17:06SPEAKER_01: But that horizontal integration and screening people for multiple infections really does reduce costs.
- 17:13SPEAKER_01: And the other thing I would say is very it's not just in Asia, but also a lot in sub-Saharan Africa, is like people with tuberculosis.
- 17:19SPEAKER_01: Anyone who's diagnosed with tuberculosis should be definitely screened for HIV in these regions.
- 17:24SPEAKER_04: Right.
- 17:25SPEAKER_04: Thank you.
- 17:25SPEAKER_04: Yeah, so integrated responses, and damagic approaches are so important.
- 17:29SPEAKER_04: Um, Bahuma, you had mentioned the status neutral approach uh briefly, and so wanting to get a little deeper into that and to hear from you about what that approach looks like in your practice, for instance.
- 17:42SPEAKER_03: Yeah.
- 17:42SPEAKER_03: Uh uh a test for HIV, as I always think about it, should really trigger a conversation around what is the next step, regardless of the result of that test.
- 17:54SPEAKER_03: If the test is non-reactive, then a conversation should be had about uh the options for um pre-exposure prophylaxis and allowing uh the patient or the client to be able to make a decision on protecting themselves and ensuring that their HIV test stays non-reactive.
- 18:16SPEAKER_03: In the event when you have an a reactive um HIV test, then the conversation should be about offering treatment and ensuring that there's linkage to care.
- 18:26SPEAKER_03: Now, the success of how this status neutral approach is implemented across the context where I've had the opportunity of doing HIV work is also very heterogeneous.
- 18:39SPEAKER_03: Um, unfortunately, in the US, we are still struggling quite a bit in terms of engaging uh African-American women in prep uptake.
- 18:48SPEAKER_03: So those conversations are either not being had frequently enough, or even when the conversations are had, there's still a lot of stigma around women feeling empowered to make choices for themselves to protect their health.
- 19:03SPEAKER_03: In the context of men who have sex with men, there are disparities between white men who have sex with men as well as when in comparison to Hispanic and African American men who have sex with men, where we can still do a lot better in terms of how many of these individuals are actively engaging in PrEP when they have a non-reactive test.
- 19:27SPEAKER_03: In our health facility, we have programs that allow direct linkage to care for individuals who have a reactive test.
- 19:37SPEAKER_03: So if you are your HIV test is reactive, you do receive counseling immediately and you are offered treatment if there's no contraindication at the time of diagnosis to receiving antiretroviral therapy.
- 19:51SPEAKER_03: And in Atlanta, this has seen us actually successfully get a lot more people into care.
- 19:57SPEAKER_03: Now, coming back to the Cameroonian context, it's important to note that some of the activities that are tied to the status neutral approach, such as access to PrEP, is challenging in these settings because PrEP is not always readily accessible.
- 20:14SPEAKER_03: So that is still a deficit and a missed opportunity that we can continue to work on in terms of closing the gap so that when people have a non-reactive test, we are actually able to offer them services that are available and accessible to them in their communities.
- 20:32SPEAKER_03: There's a lot more success in linking people to care because antiretroviral therapy programs are funded and people are able to access these medications in a subsidized fashion.
- 20:44SPEAKER_03: But still a lot of work to be done in terms of closing the gaps and disparities that surround pre-exposure prophylaxis for those who have a non-reactive HIV test.
- 20:56SPEAKER_04: Right, thank you.
- 20:56SPEAKER_04: Yeah, so status neutral approach, I think, is the ideal, but then when it comes to implementing, we may have to tailor different approaches depending on the key populations we're reaching and what resources are available.
- 21:06SPEAKER_04: So thank you so much for really encapsulating that so vividly.
- 21:10SPEAKER_04: So we know that testing obviously is one piece of a larger picture to ending the epidemic.
- 21:17SPEAKER_04: And there are, it's part of sort of this, these four sort of connected um pillars.
- 21:22SPEAKER_04: One is around diagnosing people with HIV as early as possible, treating rapidly and effectively, as is mentioned, preventing new HIV transmissions using proven interventions such as PrEP and other harm reduction approaches, and responding quickly to clusters or outbreaks.
- 21:41SPEAKER_04: And so, Chloe, how does HIV testing connect these four actions for you?
- 21:47SPEAKER_00: It's really like the central node of you know, sort of a of a sort of a dial.
- 21:53SPEAKER_00: So if you can test people, then you have the opportunity to offer them treatment and you're gonna offer same day treatment.
- 22:00SPEAKER_00: You can offer treatment very quickly, and you can offer a whole range of different opportunities for types of different treatment.
- 22:06SPEAKER_00: Um, if you can t at the same opportunities where you test people, as has been said, you can use that contact to offer prevention if the test is negative.
- 22:16SPEAKER_00: And in the UK, we have a concept of uh MEC, MECC, making every contact count.
- 22:22SPEAKER_00: We have sort of MEC activities.
- 22:24SPEAKER_00: So, really, if you're doing a test, this is a wonderful opportunity to leverage the PEP opportunities for people, condoms, uh, other prevention opportunities, PEP.
- 22:33SPEAKER_00: Um, and then of course, it also gives you the response ability to respond in terms of public health needs, in terms of contact tracing and testing.
- 22:41SPEAKER_00: So it really is at the heart of all activities and very, very central to any successful treatment program.
- 22:48SPEAKER_04: Definitely.
- 22:49SPEAKER_04: Yeah.
- 22:49SPEAKER_04: So Sigma 8 plays such a huge role.
- 22:51SPEAKER_04: And so I'm wondering um what are some of the concrete strategies that we can use to expand testing while you know creating a non-judgmental health-positive space for patients preserving their dignity and trust.
- 23:05SPEAKER_04: So curious, Chloe, in the UK, what are some approaches to sort of reducing stigma when it comes to testing?
- 23:14SPEAKER_00: So I think there's no doubt that at the individual level, the way one speaks with people is extremely important.
- 23:20SPEAKER_00: But there are, I think it's unavoidable that there are structural factors that really make it possible or impossible for people to test.
- 23:27SPEAKER_00: And I think the sheer success of the emergency department opt-out testing program and the additional uh numbers of diagnoses that have been made really speaks to the fact that although we've made it possible for any person to have it test in a sexual health clinic, that has not helped everybody because there's some people that never intend to set foot into a sexual health clinic in their lives, but they will go to primary care, they will go to a woman's health hub, they'll go to emergency departments, and we have to reach people where they are.
- 23:54SPEAKER_00: That's the and that is our responsibility.
- 23:56SPEAKER_00: People are not hard to reach.
- 23:57SPEAKER_00: Our services are inaccessible.
- 23:59SPEAKER_00: We've got to accept that.
- 24:00SPEAKER_00: So I think there are structural factors that are absolutely essential.
- 24:04SPEAKER_00: Um, and then of course, at the interpersonal level, we must address our own biases, we must try to empower people while they're in the room.
- 24:11SPEAKER_00: But really, I believe that it's it's structural solutions, such as this nationally supported opt-out testing program and the acknowledgement that we need to roll out other interventions, such as digital uh opportunities for self-testing for PrEP, that are important.
- 24:27SPEAKER_00: But we cannot avoid the fact that we've got to think about where people will go and offer them testing in these places.
- 24:34SPEAKER_00: And I think that is really fundamental to improving the outcomes.
- 24:38SPEAKER_04: Yes, yes.
- 24:39SPEAKER_04: And that's such a great transition to this question I have for Sunil around how has bundling testing with services that people want and need expanded reach in India.
- 24:50SPEAKER_01: I want to actually pick up where Chloe left off on meeting people where they are and what they need and where they want to go.
- 24:57SPEAKER_01: Because HIV screening is our priority.
- 25:00SPEAKER_01: It's not necessarily the community's priorities, especially vulnerable communities.
- 25:04SPEAKER_01: So trying to understand what they need and bundling HIV services into those venues actually will make a huge difference.
- 25:12SPEAKER_01: For example, in India, when we were working with unstably housed people who inject drugs, we realized that food banks and showers were the services that the population really wanted.
- 25:22SPEAKER_01: So we actually integrated HIV screening and hepatitis screening and syphilis screening into a place that was providing food for unstably housed people, and we found a huge uptake in HIV testing in that population.
- 25:34SPEAKER_01: Because while they went there for food or they were waiting for their shower, they said I might as well get screened for HIV while I'm waiting.
- 25:40SPEAKER_01: And we ended up diagnosing a lot of a lot of people with HIV there.
- 25:44SPEAKER_01: And similarly, with trans people, it's not just in India, but I think globally, like gender-affirming care really is their priority.
- 25:52SPEAKER_01: So trying to integrate HIV screening or viral hepatitis screening into programs that are, like, for example, laser hair removal is like a big draw for the trans community in India.
- 26:04SPEAKER_01: So when we integrated HIV testing into facilities that were providing laser hair removal, again resulting in a big uptake.
- 26:10SPEAKER_01: So these are examples I'm providing you from India, but I think they have global relevance and can be expanded to pretty much anywhere across the world because similar challenges and structural issues uh exist, especially with the most vulnerable populations.
- 26:24SPEAKER_04: Yes, no, I love the laser hair removal example.
- 26:26SPEAKER_04: It just reminds me of this idea of like the difference between what matters to someone and what's the matter with someone.
- 26:32SPEAKER_04: A lot of times the risk-based approaches tend to pathologize the populations and communities we're trying to work with versus like figuring out what matters.
- 26:40SPEAKER_04: And clearly the laser hair removal is something that really matters to some of the communities you're working with.
- 26:45SPEAKER_04: Um, and so Bahuma, what about you had mentioned the antenatal and perinatal testing?
- 26:50SPEAKER_04: And so if you could speak to that, how that's helped to expand uptake of testing.
- 26:55SPEAKER_03: Yeah, that has been very successful across countries in sub-Saharan Africa and including Cameroon, where um the availability of rapid diagnostic testing makes it very easy for um midwives and antenatal clinics not only to offer the test but also perform the test in the clinic and get a result that they're able to then apply a status neutral approach to.
- 27:22SPEAKER_03: So after a confirmatory test, a potential mother with uh a reactive uh HIV screening test will then be offered treatment that can help prevent her transmitting the virus to her unborn baby.
- 27:37SPEAKER_03: Same with um if you are you have a non-reactive test, then that information is also shared, and they have the ability to repeat this testing also at the time of labor and delivery.
- 27:49SPEAKER_03: But again, I would stress on going back to Chloe's point about testing for blood-borne viruses as opposed to only HIV, that's still a limitation that we have in these settings because while there's a rapid diagnostic test available for HIV, there are no rapid diagnostic testing kits available for HBV and HCV in these contexts.
- 28:13SPEAKER_03: And having that testing done is usually associated with an out-of-pocket cost for the mothers who are engaging with antenatal care.
- 28:22SPEAKER_03: So, again, a missed opportunity to bundle both HIV testing and prevention with uh prevention of other bloodborne viruses and an area of growth, which we must point out and acknowledge that the main limitation is funding for these services because these come at a cost and it's a lot more challenging to deliver if they're not the resources to allow healthcare providers to actually be able to provide these services to communities.
- 28:52SPEAKER_04: Yes.
- 28:53SPEAKER_04: So we talked a few about a few different strategies again to expand testing and so and to make it routine so that it's easier for folks to um you know uptake uh HIV testing.
- 29:06SPEAKER_04: Um we know also that communication and how we so talk to our patients and engage with them is really important.
- 29:12SPEAKER_04: And so, Bahuma, can you share with us some of the pearls that you may have around like how you communicate with patients when it comes to testing?
- 29:21SPEAKER_03: Yeah, absolutely.
- 29:22SPEAKER_03: I I think that a lot of the responses that we get from patients when we offer testing for HIV is very much dependent on how we approach these conversations.
- 29:34SPEAKER_03: And I like for providers, healthcare providers, to think about it around core principles, which I find particularly helpful.
- 29:42SPEAKER_03: It's important to ask open-ended questions that allow you to engage with the patient and open up a dialogue to also hear what they think about testing.
- 29:52SPEAKER_03: And when they tell you their answers, it's also important to pause and reflect on what they have said and shared with you before you respond to their question or their their reflection.
- 30:06SPEAKER_03: And it's important that we we normalize testing for HIV as part of routine care, not build it into this thing that is extraordinary, but rather as part of ensuring your your health, HIV testing is a component of that.
- 30:23SPEAKER_03: What that does is that it removes the judgment aspect of testing, and people don't feel like they're being targeted because you're offering them HIV testing.
- 30:34SPEAKER_03: And it's also important to affirm the patient's autonomy.
- 30:39SPEAKER_03: Know that you can offer a test, but the patient still has the full right to be able to refuse testing, and that is not a judgment on your abilities as a provider.
- 30:51SPEAKER_03: What I take from those refusals is usually the fact that at least a conversation and a dialogue was had, which allows you to build, you can build upon that at the next visit.
- 31:03SPEAKER_03: And it's also important to meet ambivalence with patience rather than trying to feel the need to persuade.
- 31:11SPEAKER_03: We know that we want people to get tested, but you have to take a step back and also respect the fact that that person may not be ready on that day and resist the temptation to then mount a very robust debate on why they have to get tested when you offered the testing.
- 31:31SPEAKER_03: And I always like to leave the door open for future conversation, and that can be by just letting the person know that, you know, we had this conversation today.
- 31:41SPEAKER_03: Thank you for what you shared, and I hope that we can engage in this conversation again in the future.
- 31:48SPEAKER_04: Wonderful.
- 31:49SPEAKER_04: So keeping those communication channels open.
- 31:51SPEAKER_04: Uh Chloe and Sunil, um, how does what Bahuma shared align with your with your own clinical experience around communicating, around testing?
- 32:00SPEAKER_00: It aligns absolutely perfectly, and I can't think of a single word that I could add to that.
- 32:05SPEAKER_01: Mine's the same.
- 32:06SPEAKER_01: I would probably say the one thing I would say is the person sitting across from you is just another person, like you and me.
- 32:11SPEAKER_01: So treat them how you would want to be treated with respect and dignity.
- 32:15SPEAKER_04: But to you, you were describing in some part some of the spirit of uh what we call motivational interviewing.
- 32:23SPEAKER_04: Um, and can you just I guess share with us some of the sort of the process behind that approach?
- 32:29SPEAKER_03: Yeah, I I like to think of it kind of as a four-step process.
- 32:33SPEAKER_03: And you know, what I I I I practice in in my own approach is that I like to ask what the the person's impress feelings are about HIV testing, and then I listen to what they have to say, and then I ask permission to share additional uh information and then support their decision.
- 32:56SPEAKER_03: And you know, in order to really illustrate this and give people uh helpful tools, uh, there phrases like, um, what are your thoughts about HIV testing today?
- 33:08SPEAKER_03: What that question does, it doesn't start with, would you like to get tested for HIV today, or it's like you have to get an HIV test today.
- 33:17SPEAKER_03: It opens conversation for that person to share how they feel about getting tested for HIV.
- 33:23SPEAKER_03: And it's important to listen carefully and reflect what you hear before offering additional information.
- 33:29SPEAKER_03: And to offer additional information, I usually say something like, Would it be okay if I share why we recommend routine HIV testing?
- 33:38SPEAKER_03: And once you've shared that additional information, it's important again to reinforce the patient's autonomy.
- 33:46SPEAKER_03: I say something like, the decision is completely yours.
- 33:49SPEAKER_03: My goal is to make sure that you have the information that you need to make the decision that you feel is best for you.
- 33:57SPEAKER_04: Wonderful.
- 33:58SPEAKER_04: And so let's apply that to a clinical scenario.
- 34:02SPEAKER_04: So let's say you have a patient who says, I don't need an HIV test.
- 34:06SPEAKER_04: I'm not the type of person who gets HIV.
- 34:09SPEAKER_04: So how might you respond to that?
- 34:12SPEAKER_03: Yeah, I usually try to avoid absolute responses, something like everybody needs a test immediately places the patient in a defensive posture.
- 34:21SPEAKER_03: It may be well intentioned by the provider, but what it does is it may feel or come across as dismissive and lead the patient to completely shut down.
- 34:32SPEAKER_03: So, what is a better response to kind of engage the patient more positively?
- 34:38SPEAKER_03: Is I by saying things like, many people feel that way.
- 34:42SPEAKER_03: Can you tell me what makes you feel that your exposure is low?
- 34:46SPEAKER_04: So many good calls there.
- 34:47SPEAKER_04: Um, Chloe and Sunil, anything that you'd like to add to what Mahoma mentioned?
- 34:53SPEAKER_04: Okay, so moving on.
- 34:54SPEAKER_04: Um, so once someone agrees to testing, the next step is to use the correct diagnostic algorithm.
- 35:01SPEAKER_04: And the CDC laboratory algorithm follows three principal steps.
- 35:05SPEAKER_04: The first being beginning with an HIV 1-2 antigen antibody immunoassay.
- 35:12SPEAKER_04: And then if reactive, perform an HIV, HIV2 antibody differentiation assay.
- 35:17SPEAKER_04: And then if the assay is negative or indeterminate, performing an HIV-1 nucleic acid test.
- 35:25SPEAKER_04: And the nucleic acid test distinguishes acute HIV infection from a false reactive initial screening results.
- 35:34SPEAKER_04: Um, when acute infection is suspected because of recent exposure or because of the constellation of presenting symptoms, conditions should not rely on antibody testing alone in HIV when that should be ordered as clinically appropriate.
- 35:53SPEAKER_04: So moving on to the World Health Organization's uh approach, they use a different sequential approach.
- 35:59SPEAKER_04: And Sunil, could you walk us through it and then we'll have Bahuma and Chloe also share uh one regional implementation consideration if if moved to.
- 36:11SPEAKER_04: Okay, Sunil.
- 36:13SPEAKER_01: Sure.
- 36:13SPEAKER_01: I think the WHO really uses three rapid tests.
- 36:17SPEAKER_01: So the way they have set it up is like you do a first rapid diagnostic test, which serves as like the initial screening assay.
- 36:23SPEAKER_01: And if that is reactive, then you move to a different uh rapid diagnostic test, but it should use a different antigen or antibody from what the first test used.
- 36:33SPEAKER_01: And that's more for confirming confirmation.
- 36:36SPEAKER_01: And if that's reactive, then you move to a third test, which is a different RDT, which sort of is like the final determination and whether someone is positive or not.
- 36:45SPEAKER_01: And this could actually be done at the field level with three rapid tests pretty quickly.
- 36:49SPEAKER_01: And some settings actually run all those three tests in parallel, so within like 25-30 minutes, you actually have results.
- 36:57SPEAKER_01: Generally, they run the first test, and then if the first test is negative, they stop.
- 37:01SPEAKER_01: If the first test is positive, they run the second and third together.
- 37:03SPEAKER_01: There are different ways of doing this.
- 37:05SPEAKER_01: But if it is an inconclusive test, then what they recommend is repeating all these three tests again in 14 days.
- 37:14SPEAKER_04: Great, Sunil.
- 37:15SPEAKER_04: But Chloe, do you have anything to add to that?
- 37:17SPEAKER_03: Yeah, I I would add to what Sunil has just said that with the WHO uh three test strategy, which is what a lot of what is implemented in resource-constrained settings, one of the things we're still missing is the very early acute diagnosis of HIV.
- 37:36SPEAKER_03: So individuals who are presenting within 10 days of acquiring HIV, and we know that the rapid diagnostic testing is not going to pick that up.
- 37:45SPEAKER_03: Unfortunately, in a lot of um the settings uh in Cameroon or other parts of sub-Saharan Africa, there's not always the ability to uh do um a nucleic acid-based uh testing to really pick up on those cases of acute HIV infection, which are also the individuals who would have very high viral loads and have the potential of actually transmitting the virus before they are diagnosed as having a reactive HIV test.
- 38:17SPEAKER_04: So we've covered a lot around confirming diagnoses, strategies to expand testing, um, how do we communicate around testing?
- 38:26SPEAKER_04: And you know, a lot of this is all you know within the context of the fact that we are facing many barriers.
- 38:32SPEAKER_04: Barriers to testing are very common and they sort of come at many different levels, typically regroup it into the individual level, the provider level, and structural levels.
- 38:43SPEAKER_04: Um so let's uh move on to look at how programs are adapting on the ground.
- 38:49SPEAKER_04: And we often know the best solutions are those that are adapted to the local context and what the unique challenges of that context might be.
- 38:57SPEAKER_04: So we'll start with the US, where HIV testing may remain siloed from routine care.
- 39:04SPEAKER_04: And so, Bahuma, um, if you could share approaches that have helped to address testing barriers in your clinical experience.
- 39:12SPEAKER_03: Yeah, a good example would be uh the systems that we've put in place at our uh county hospital in Atlanta.
- 39:20SPEAKER_03: Atlanta is one of the cities in the southeastern U.S.
- 39:23SPEAKER_03: with the highest prevalence and incidence of HIV, so still really has a very uh uncontrolled epidemic.
- 39:32SPEAKER_03: And one of the things we've instituted is that every individual who comes through the emergency department at the county hospital, which is a safety net hospital and sees a lot of patients insured and uninsured, uh is offered an HIV test in the emergency department on an opt-out basis.
- 39:53SPEAKER_03: If they have not had a test within the past year, they are automatically offered the test, and that has really increased uh the number of new HIV diagnoses that we've been able to identify.
- 40:06SPEAKER_03: Besides the routine implementation of offering testing to every adult in the emergency department, we also have case managers that are immediately involved if there is a reactive HIV test, and the individual will receive counseling and will be offered treatment before they leave the hospital.
- 40:27SPEAKER_03: And this is also enhanced linkage to care.
- 40:30SPEAKER_03: Uh getting a lot of these folks connected to our HIV outpatient services once they start treatment has led to us seeing higher numbers of individuals getting virologically suppressed and getting healthier.
- 40:45SPEAKER_04: Thank you, Pakoma.
- 40:46SPEAKER_04: Um Sunil, um, how about you?
- 40:48SPEAKER_04: What approaches have been effective in India?
- 40:52SPEAKER_01: I think I talked briefly about the integrating HIV services with other non-essential uh well, essential services, but not necessarily medical services.
- 41:01SPEAKER_01: The other thing that we've actually done a fair amount of work in India is around digital platforms and making access to HIV testing through virtual spaces.
- 41:09SPEAKER_01: As you know, like India has like a billion people with a lot of cell phones and everybody's on WhatsApp.
- 41:13SPEAKER_01: There's a Grindr, Planet Romeo, Blood, everything exists in India.
- 41:18SPEAKER_01: So we actually ran this platform which was uh targeted at people who were seeking partners either on uh Grindr or Blued or Planet Romeo, and then the entire process happened virtually over WhatsApp with a virtual outreach worker who guided them through the process.
- 41:37SPEAKER_01: We provided testing to almost 30,000 people through a PEPPOR grant, and our HIV prevalence confirmed positive was about 5%.
- 41:44SPEAKER_01: And if you compare that against the general population prevalence of 0.2% is almost 25 times higher.
- 41:50SPEAKER_01: And 70% of these people had never been screened for HIV before because they didn't think they were at risk.
- 41:57SPEAKER_04: Another version of reaching people where they are.
- 41:59SPEAKER_04: Uh, if they're gonna be in the virtual spaces, reach them there.
- 42:01SPEAKER_04: So that's very exciting work.
- 42:03SPEAKER_04: Um, and Chloe, what about you?
- 42:04SPEAKER_04: What lessons can we draw from the UK?
- 42:06SPEAKER_04: I know you've shared some already.
- 42:08SPEAKER_00: Yeah.
- 42:08SPEAKER_00: And it's very effective.
- 42:10SPEAKER_00: And in terms of digital interventions, um, I completely agree that we need to offer these.
- 42:15SPEAKER_00: Um so far, we've been doing some work in my sort of poor part of town on you know free digital uh free access to HIV testing and uh PrEP.
- 42:27SPEAKER_00: And actually it has not improved um the disparities at all.
- 42:31SPEAKER_00: It's just meant that uh these spaces are even more accessible uh to white gay men, but no one else has taken them up.
- 42:40SPEAKER_00: So I think it's really interesting.
- 42:42SPEAKER_00: I think it's really important to to try and do new things and to be creative and push out the envelope, but to realize that context is important and what may work in one setting may not work in another.
- 42:54SPEAKER_04: So before we hear from Angelina, could you briefly introduce her and explain to her audience why her perspective is important to hear?
- 43:04SPEAKER_00: So Angeline is an incredible uh HIV advocate and activist.
- 43:08SPEAKER_00: She's the co-founder of uh 4M, so mental mothers.
- 43:12SPEAKER_00: Uh, and she also supports uh the uh research that we do at the Share Collaborative in London with her lived experience perspective.
- 43:20SPEAKER_00: She's a very wise person.
- 43:22SPEAKER_00: So Angelina's been living with HIV for more than 20 years, and her message is extremely clear.
- 43:27SPEAKER_00: HIV is a virus, not a moral indictment.
- 43:30SPEAKER_00: Uh stigma and judgment can prevent people from testing and from accessing care.
- 43:35SPEAKER_00: And being able to test enabled Angelina to access life saving treatment and care and to continue living uh a full and healthy life.
- 43:46SPEAKER_00: I think it's really important that all clinicians uh hear this perspective and understand why uh getting this diagnosis uh can be very important uh to support a positive life uh rather than Than sort of uh the end of life.
- 44:02SPEAKER_00: And I think it's so important to see her uh effervescent uh and incredibly uh life-affirming perspective.
- 44:10SPEAKER_02: Because you can only uh look after your health if you know what your status is.
- 44:14SPEAKER_02: And once you know your status, whether it's negative or it's positive, then you can do something about it, you can access treatment, you can access uh services.
- 44:22SPEAKER_02: So it's important to test, you know.
- 44:24SPEAKER_02: Because that's the only way you know.
- 44:25SPEAKER_02: Because some people tend to maybe they they may have a partner who is not living with HIV and will not test because they assume because my partner isn't, then I'm not.
- 44:36SPEAKER_02: Or then again, the thing goes back to the thing about well, I don't fit the typical stereotypical person with HIV, so I can't uh possibly uh be positive.
- 44:45SPEAKER_02: So it's about just getting the and and a lot of it is also driven by the uh the judgments, the moralization, the the blame, you know, all those negatives.
- 44:56SPEAKER_02: And so people maybe sometimes even if they do want to test, because all they know is that those and that negative messaging, they think, well, I'm not even gonna uh go there because what the hell am I gonna do?
- 45:06SPEAKER_02: Because all I know is a negative, right?
- 45:08SPEAKER_02: Not knowing that actually just by doing a test that could save will save your life.
- 45:14SPEAKER_03: Um for me, her message really resonates because it makes me think about how much stigma there still is around uh having a diagnosis of HIV.
- 45:25SPEAKER_03: Uh, I think about when um individuals have a reactive test, how the view is still, you know, one of my life is going to end.
- 45:34SPEAKER_03: And I think having conversations around testing allows us to start destigmatizing some of that um culture and messaging around testing and really flipping it on its head and re-emphasizing the fact that HIV is treatable.
- 45:52SPEAKER_03: Uh a reactive test is not the end of life, it's actually the opportunity to engage with care and leave the fullest possible life.
- 46:02SPEAKER_03: And additionally, a non-reactive test is empowering because it then gives you the opportunity to make choices about your own health that can further prevent HIV and ensure that uh you remain uh within a non-reactive HIV test.
- 46:18SPEAKER_03: So those are my reflections on her message.
- 46:24SPEAKER_01: And to me, I think Angelina's message was very clear: treat every person with respect and dignity.
- 46:30SPEAKER_04: So we know that effective testing and language often can be a team effort and involve multiple people depending on context.
- 46:40SPEAKER_04: And so, Sunil, um, how can clinicians build an effective linkage-to-care model when staffing and resources differ substantially across settings, particularly when they are resource-constrained?
- 46:55SPEAKER_01: So I think the slide shows you a wish list of everything that may be possible in a setting which has a lot of resources.
- 47:03SPEAKER_01: But that's not usually the case.
- 47:05SPEAKER_01: So this needs to be tailored to the local context, what your resources are available to you, how much funding is available to you.
- 47:12SPEAKER_01: But the one thing I would say is extremely critical is having an outreach worker or a counselor or someone or a social worker who is going to link this person either with a prevention service or with a treatment service.
- 47:26SPEAKER_01: If it's not the physician themselves who's prescribing the ART or the PrEP, that linkage has to be a part of the program.
- 47:33SPEAKER_01: Because diagnosing someone and not telling them what the next step is, you might as well not diagnose them.
- 47:39SPEAKER_01: So you want to diagnose them, do the screening, and if they're negative, have some process to link them to a negative, uh to a prep program, or if they're positive, you want to link them to an HIV program.
- 47:50SPEAKER_01: And it doesn't have to be active linkage, it could even be passive, which is giving someone a note saying, hey, these are the five facilities where you could go to to get PrEP is a lot more effective than telling them, hey, you're negative, you should go and find PrEP.
- 48:02SPEAKER_01: So you should take a multidisciplinary approach, but it really needs to be tailored to the local context and what staffing and resources are available to you.
- 48:12SPEAKER_04: Thank you.
- 48:12SPEAKER_04: Yeah, that linkage part is critically important.
- 48:15SPEAKER_04: Um so moving on, um, we have developed practical resources called clinical points for both clinicians and people considering HIV testing.
- 48:25SPEAKER_04: Um, and these tools can support uh conversations about HIV testing, and they're available within this activity as well as through the CME Outfitters Hub.
- 48:36SPEAKER_04: Um and you can see there's a link on the slide.
- 48:39SPEAKER_04: Um, so um we're gonna be concluding our program, and we're gonna conclude by translating today's uh discussion into SMART goals, so goals that are specific, measurable, attainable, relevant, and timely.
- 48:55SPEAKER_04: And so consider how you might apply this framework to your practice.
- 49:00SPEAKER_04: So, first, um, adopt a status neutral approach to HIV screening with all patients to normalize testing and reduce stigma across diverse global clinical settings.
- 49:12SPEAKER_04: Uh, second, use HIV testing results to promptly guide confirmatory testing and linkage to prevention or treatment based on local resources, scope of practice, and regional guideline recommendations.
- 49:25SPEAKER_04: And then lastly, apply patient-centered, culturally responsive communication and team-based collaboration to support shared decision making for testing to the realistic time frame and improvement target that fits your specific clinical context and setting and the communities that you serve.
- 49:46SPEAKER_04: Thank you to our faculty for sharing their expertise and their regional perspectives, and thank you to our audience for your continued commitment to improve testing linkage and care for people living with HIV.